Paid Clinical Trials in Nova Scotia Canada

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Nova Scotia

Top of Directory » All Locations » Canada » Nova Scotia




  • Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: linagliptin;   Drug: placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009

  • A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
    Sponsors:   Hoffmann-La Roche;   Genentech
    Not yet recruiting - verified November 2009

  • Augment™ Injectable Bone Graft Compared to Autologous Bone Graft in Foot and Ankle Fusions

    Condition:   Ankle/Hindfoot Fusion
    Interventions:   Device: Augment™ Injectable;   Procedure: Standard of care
    Sponsor:   BioMimetic Therapeutics
    Recruiting - verified November 2009

  • A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Glycopyrronium bromide;   Drug: Placebo
    Sponsor:   Novartis
    Recruiting - verified November 2009

  • Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Interventions:   Drug: Asacol (mesalamine), High Dose;   Drug: Asacol (mesalamine), Low Dose
    Sponsor:   Procter and Gamble
    Recruiting - verified October 2009

  • Oseltamivir Pharmacokinetics in Morbid Obesity

    Condition:   Morbid Obesity
    Interventions:   Other: Patients with a BMI < 30 given Oseltamivir;   Other: Patients with a BMI > 40 given Oseltamivir
    Sponsors:   IWK Health Centre;   Canadian Center for Vaccinology;   Capital District Health Authority;   Dalhousie University;   Hoffmann-La Roche
    Not yet recruiting - verified October 2009

  • Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

    Conditions:   HIV Infections;   H1N1 Influenza
    Interventions:   Biological: Arepanrix;   Biological: Arepanrix
    Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
    Not yet recruiting - verified October 2009

  • Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?

    Condition:   Influenza
    Interventions:   Biological: Fluviral influenza vaccine, 2009-2010;   Biological: Normal saline
    Sponsors:   Mount Sinai Hospital, Canada;   GlaxoSmithKline
    Recruiting - verified November 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children

    Condition:   H1N1/2009 Influenza
    Interventions:   Biological: Arepanrix;   Biological: Arepanrix
    Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
    Not yet recruiting - verified October 2009

  • A Study of Patients With Major Depressive Disorder and Residual Apathy

    Condition:   Major Depressive Disorder
    Interventions:   Drug: Duloxetine;   Drug: Escitalopram
    Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009

  • Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: Saline placebo;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

    Conditions:   Low Back Pain;   Low Back Pain, Recurrent
    Interventions:   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: Placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Study to Evaluate the Effectiveness of an Implant in the Treatment of Osteoarthritis of the Great Toe

    Condition:   First MTP Joint Osteoarthritis
    Interventions:   Device: Arthrodesis;   Device: Cartiva
    Sponsor:   Carticept Medical, Inc
    Recruiting - verified November 2009

  • Canadian Varicocelectomy Initiative (CVI): Effects on Male Fertility and Testicular Function of Varicocelectomy

    Conditions:   Male Infertility;   Varicoceles
    Intervention:   Procedure: Varicocelectomy
    Sponsors:   Mount Sinai Hospital, Canada;   McGill University;   Dalhousie University;   McMaster University
    Recruiting - verified November 2009

  • Study of Blood Samples From Newborns With Down Syndrome

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Intervention:   Drug: Dimebon
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

    Condition:   Schizophrenia
    Interventions:   Drug: paliperidone palmitate;   Drug: oral risperidone
    Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
    Recruiting - verified November 2009

  • Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

    Conditions:   Human Papillomavirus (HPV) Type 16/18 Infections;   Cervical Neoplasia
    Intervention:   Procedure: Gynaecological follow-up
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

    Condition:   Follicular Lymphoma
    Interventions:   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

    Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
    Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

    Condition:   Brain and Central Nervous System Tumors
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older With the G551D Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

    Condition:   Sarcoma
    Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

    Condition:   Sarcoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

    Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Kidney Tumors in Young Patients

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

    Condition:   Bipolar Depression
    Interventions:   Drug: quetiapine (Seroquel) XR;   Drug: quetiapine (Seroquel) XR;   Drug: placebo;   Drug: pramipexole dihydrochloride
    Sponsors:   Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.;   AstraZeneca
    Recruiting - verified October 2009

  • A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Doxorubicin;   Drug: Paclitaxel
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

    Condition:   Depression
    Interventions:   Other: Placebo;   Drug: orvepitant
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

    Conditions:   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: bendamustine and rituximab;   Drug: R-CVP or R-CHOP
    Sponsor:   Cephalon
    Recruiting - verified November 2009

  • Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals With Herpes Simplex Virus Type 2?

    Conditions:   HIV Infection;   Herpesvirus 2, Human;   HIV Infections
    Interventions:   Drug: valacyclovir;   Drug: Placebo
    Sponsors:   University Health Network, Toronto;   Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz;   The Huesped Foundation
    Not yet recruiting - verified August 2009

  • A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

    Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • Phase 3 Study Comparing 2 Doses of CP-690,550 and the Active Comparator, Humira (Adalimumab) vs. Placebo for Treatment of Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: CP 690,550;   Drug: CP-690,550;   Other: Placebo;   Other: Placebo;   Biological: Biologic TNFi
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Interventions:   Drug: Dimebon;   Drug: Placebo;   Drug: Dimebon;   Drug: Placebo
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • Phase III Acute Coronary Syndrome

    Condition:   Acute Coronary Syndrome
    Interventions:   Drug: Apixaban;   Drug: Placebo
    Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
    Recruiting - verified October 2009

  • Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

    Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
    Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab-MCC-DM1
    Sponsors:   Genentech;   Roche Pharma AG
    Recruiting - verified October 2009

  • Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

    Conditions:   Osteoarthritis;   Arthritis
    Interventions:   Drug: NSAID;   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab;   Drug: NSAID;   Biological: tanezumab;   Drug: NSAID
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Fulvestrant + ZACTIMA;   Drug: Fulvestrant + Placebo
    Sponsors:   Ontario Clinical Oncology Group (OCOG);   AstraZeneca
    Recruiting - verified November 2009

  • The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

    Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
    Interventions:   Drug: Darapladib;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

    Condition:   Chronic Plaque Psoriasis
    Intervention:   Biological: HUMIRA® (adalimumab)
    Sponsor:   Abbott
    Recruiting - verified October 2009

    • Menu
    Find Paid Clinical Trials